Save 20% on Press Releases and More with NNW Prime! Click to View Details
ThursdaySep 21, 2017 11:42 am

NetworkNewsBreaks – Jim Stearns Takes on Role of Senior Managing Director at RHK Capital

RHK Capital recently announced the addition of Jim Stearns to its investment banking and capital markets team as Senior Managing Director. Stearns, who comes to RHK Capital with over 42 years of investment banking and advisory experience, has spent the last 23 years as a Managing Director and Partner of Roth Capital Partners, LLC. Stearns first initiated and managed the firm’s corporate finance activities in the Pacific Northwest and later its national Industrial’s Group. Among Stearns accomplishments are initiating and leading the firm’s domestic and international OTCQX initiatives and executing a wide variety of transactions including M&A advisory, initial public…

Continue Reading

WednesdaySep 20, 2017 2:37 pm

NetworkNewsBreaks – ROTH Capital Partners Names New Members of Healthcare Research Team

ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, this morning said that Jotin Marango, M.D., Ph.D. and Yasmeen Rahimi, Ph.D. have joined the firm’s healthcare research team. Dr. Marango joins ROTH from H.C. Wainwright & Co., where he covered hematology, oncology, and pulmonary therapeutics, with a specific focus on epigenetic and molecularly targeted therapies. Dr. Rahimi also joins ROTH from H.C. Wainwright & Co. Prior to her time at H.C. Wainwright & Co., she was a research associate at Guggenheim Securities. “Coupled with the recent additions to our healthcare banking team,…

Continue Reading

WednesdaySep 20, 2017 11:12 am

NetworkNewsBreaks – Codan Limited (CODAF) Receives Increased Price Target from Independent Investment Research

Independent Investment Research has updated its coverage and increased its price target from $2.24 to $2.51 on shares of Codan Limited’s (OTC: CODAF) Australia-listed stock following the company’s report of financial results for the full year ending in 2017. The analyst noted that the company’s strong results for the year exceeded expectations, with an increase in revenues of 33.4% to $226.1 million. The growth in revenue is attributed primarily to new product development, which in turn enabled the company to pay down existing debt. The analyst noted that the constant development of new products continues to drive the company’s valuation.…

Continue Reading

WednesdaySep 20, 2017 11:07 am

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Has “Buy” Rating Reiterated at Mizuho Securities

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock. The analyst noted the FDA’s recently reported date of the Advisory Committee for Aerie Pharmaceutical's Rhopressa to take place on October 13, 2017. This meeting is considered routine to take place before approval of a new product, specifically a new molecular entity. The analyst also noted another key date to remember in regards to the FDA meeting: October 11, the anticipated date that the FDA will release the background information on Rhopressa. This document typically offers a…

Continue Reading

MondaySep 18, 2017 12:00 pm

NetworkNewsBreaks – Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) Has “Buy” Rating Reiterated at Mizuho Securities

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $32 on shares of Alder BioPharmaceuticals, Inc.’s (NASDAQ: ALDR) stock after Mizuho received an email from the company reviewing the 18th Congress of the International Headache Society (IHC) meeting. The email included incremental data points regarding Alder’s lead pivotal-stage product candidate, eptinezumab. The analyst believes that the IV formulation for eptinezumab is a positive distinction from other calcitonin gene-related peptide (CGRP) products in late stage development, based on its reimbursement and potentially improved compliance. For more information, visit www.AlderBio.com About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is…

Continue Reading

FridaySep 08, 2017 12:10 pm

NetworkNewsBreaks – Achaogen, Inc. (NASDAQ: AKAO) Receives ‘Buy’ Rating at Mizuho Securities

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $28 on shares of Achaogen, Inc.’s (NASDAQ: AKAO) stock. Achaogen has a broad pipeline of novel anti-bacterial drugs currently in development, including its lead candidate Plazomicin, which the analyst considers to be a value driver for the company. Following the positive results from the pivotal EPIC and CARE trials for treatment of complicated urinary tract infections (cUTIs) and Carbapenem Resistant Enterobacteriaceae (CRE), the company is preparing Plazomicin to file a New Drug Application (NDA) close to year-end. For more information, visit www.Achaogen.com About Achaogen…

Continue Reading

FridaySep 08, 2017 12:08 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock. The company designs, manufactures and markets the MRIdian® radiation therapy system, which received CE-mark approval and 510(k) approval in February of this year. The analyst sees immense potential in the MRI-guided LINAC to disrupt current radiation oncology. The MRI-LINAC offers real-time imaging improving dosimetry and reduces the toxicity to patients, which makes for stiff competition for other companies that seem to have recently began to focus on real-time imaging. Additionally, the analyst believes that the company…

Continue Reading

FridaySep 08, 2017 12:05 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage on Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) with ‘Buy’ Rating

Mizuho Securities USA LLC has initiated coverage and issued a ‘Buy’ rating and price target of $32 on shares of Alder BioPharmaceuticals, Inc.’s (NASDAQ: ALDR) stock. Among other highlights, the analyst noted the company’s 'de-risked' asset, Eptinezumab, slated for an upcoming phase 3 PROMISE 2 read-out anticipated during the first half of 2018. The company has previously posted positive results from its first pivotal trial, PROMISE 1, which led the analyst to expect comparable results from PROMISE 2, as the studies' designs are similar. For more information, visit www.AlderBio.com About Alder BioPharmaceuticals, Inc. Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical…

Continue Reading

FridaySep 08, 2017 12:03 pm

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Buy’ Rating on Zogenix, Inc. (NASDAQ: ZGNX)

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $28.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock after the company hit a new 52-week high on Wednesday. The company’s lead product candidate for the treatment of seizures associated with Dravet syndrome, ZX008, was noted by the analyst as having a strong efficacy. The analyst also cited clinical data that suggests ZX008 shows a superior long-term efficacy profile over its competitors with tolerable side effects. Upcoming catalysts for the company include phase 3 read-outs in the third quarter of 2017, and either the fourth…

Continue Reading

FridaySep 08, 2017 12:01 pm

NetworkNewsBreaks – Novocure (NASDAQ: NVCR) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $25 on shares of Novocure’s (NASDAQ: NVCR) stock. Mizuho analysts noted the company’s novel treatment for cancer, Optune, has demonstrated a strong five-year overall survival benefit on cancer patients with glioblastoma (GBM), and the analyst believes it will continue to do well in the medical community. Therefore, the analyst believes Novocure will hit estimated full-year revenue of $165 million in 2017, which would represent a 95% year-over-year increase. For more information, visit www.Novocure.com About Novocure Novocure is an oncology company developing a profoundly different cancer…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000